Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CRESTOR

« Back to Dashboard
Crestor is a drug marketed by IPR and is included in one NDA. It is available from thirteen suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in CRESTOR is rosuvastatin calcium. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. There are ten tentative approvals for this compound. Additional details are available on the rosuvastatin calcium profile page.

Summary for Tradename: CRESTOR

Suppliers / Packagers: see list70
2013 Sales:$5,310,818,000

Pharmacology for Tradename: CRESTOR

Clinical Trials for: CRESTOR

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
Status: Completed Condition: Hypertension; Hyperlipidemia

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin
Status: Active, not recruiting Condition: Healthy

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects
Status: Completed Condition: Drug-Drug Interaction (DDI); Intestinal Absorption; Healthy Subjects; Pharmacokinetics of Rosuvastatin; Pharmacokinetics of Fidaxomicin

The Rosuvastatin In TrAnsplant Recipients Study
Status: Completed Condition: Disorder Related to Renal Transplantation; Hypercholesterolemia

The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine
Status: Completed Condition: Hypertension; Hyperlipidemia

A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers
Status: Completed Condition: Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR

Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg
Status: Completed Condition: Diabetes Mellitus

Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Status: Completed Condition: Metabolic Syndrome

Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg
Status: Completed Condition: Diabetes Mellitus

Rosuvastatin in the Treatment of Rectal Cancer
Status: Not yet recruiting Condition: Rectal Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
rosuvastatin calcium
TABLET;ORAL021366-002Aug 12, 2003RXNoRE37314*PED<disabled> <disabled>
rosuvastatin calcium
TABLET;ORAL021366-004Aug 12, 2003RXNo<disabled><disabled>
rosuvastatin calcium
TABLET;ORAL021366-003Aug 12, 2003RXNoRE37314*PED<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CRESTOR

Drugname Dosage Strength RLD Submissiondate
rosuvastatin calciumTablets5 mg, 10 mg, 20 mg and 40 mgCrestor8/13/2007
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn